These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

31 related articles for article (PubMed ID: 7535791)

  • 1. Altered glycosylation profile of purified plasma ACT from Alzheimer's disease.
    Ianni M; Manerba M; Di Stefano G; Porcellini E; Chiappelli M; Carbone I; Licastro F
    Immun Ageing; 2010 Dec; 7 Suppl 1(Suppl 1):S6. PubMed ID: 21172065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute phase proteins as biological markers of addictive disorders in teenagers and children.
    Korolenko TA; Poteryaeva ON; Li XV; Uchkina TV
    Int J Circumpolar Health; 2001 Apr; 60(2):288-93. PubMed ID: 11507984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study protocol for a randomised, double-blind, placebo-controlled 12-week pilot phase II trial of Sailuotong (SLT) for cognitive function in older adults with mild cognitive impairment.
    Steiner GZ; Bensoussan A; Liu J; Hohenberg MI; Chang DH
    Trials; 2018 Sep; 19(1):522. PubMed ID: 30253809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 21st century epidemic: infections as inductors of neuro-degeneration associated with Alzheimer's Disease.
    Licastro F; Carbone I; Raschi E; Porcellini E
    Immun Ageing; 2014; 11(1):22. PubMed ID: 25516763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview.
    Brosseron F; Krauthausen M; Kummer M; Heneka MT
    Mol Neurobiol; 2014 Oct; 50(2):534-44. PubMed ID: 24567119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing candidate serum biomarkers for Alzheimer's disease: a longitudinal study.
    Zabel M; Schrag M; Mueller C; Zhou W; Crofton A; Petersen F; Dickson A; Kirsch WM
    J Alzheimers Dis; 2012; 30(2):311-21. PubMed ID: 22426016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential.
    Noelker C; Hampel H; Dodel R
    Mol Diagn Ther; 2011 Apr; 15(2):83-102. PubMed ID: 21623645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mediterranean diet, inflammatory and metabolic biomarkers, and risk of Alzheimer's disease.
    Gu Y; Luchsinger JA; Stern Y; Scarmeas N
    J Alzheimers Dis; 2010; 22(2):483-92. PubMed ID: 20847399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological marker candidates of Alzheimer's disease in blood, plasma, and serum.
    Schneider P; Hampel H; Buerger K
    CNS Neurosci Ther; 2009; 15(4):358-74. PubMed ID: 19840034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammation as a potential mediator for the association between periodontal disease and Alzheimer's disease.
    Watts A; Crimmins EM; Gatz M
    Neuropsychiatr Dis Treat; 2008 Oct; 4(5):865-76. PubMed ID: 19183779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease.
    Aluise CD; Sowell RA; Butterfield DA
    Biochim Biophys Acta; 2008 Oct; 1782(10):549-58. PubMed ID: 18760351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monomeric and polymeric forms of alpha-1 antichymotrypsin in sera from patients with probable late onset Alzheimer's disease.
    Licastro F; Sirri V; Trerè D; Davis LJ
    Dement Geriatr Cogn Disord; 1997; 8(6):337-42. PubMed ID: 9370085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?
    Licastro F; Pedrini S; Caputo L; Annoni G; Davis LJ; Ferri C; Casadei V; Grimaldi LM
    J Neuroimmunol; 2000 Feb; 103(1):97-102. PubMed ID: 10674995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease.
    Kalaria RN
    Res Immunol; 1992; 143(6):637-41. PubMed ID: 1280849
    [No Abstract]   [Full Text] [Related]  

  • 15. Multi-functional capability of proteins: alpha1-antichymotrypsin and the correlation with Alzheimer's disease.
    Zhang S; Janciauskiene S
    J Alzheimers Dis; 2002 Apr; 4(2):115-22. PubMed ID: 12214135
    [No Abstract]   [Full Text] [Related]  

  • 16. Increased serum alpha 1-antichymotrypsin in patients with probable Alzheimer's disease: an acute phase reactant without the peripheral acute phase response.
    Licastro F; Morini MC; Polazzi E; Davis LJ
    J Neuroimmunol; 1995 Mar; 57(1-2):71-5. PubMed ID: 7535791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serological alpha 1-antichymotrypsin in patients with probable senile dementia of Alzheimer type: a short-term longitudinal study.
    Licastro F; Davis LJ; Polazzi E; Rossi S; Cucinotta D
    Alzheimer Dis Assoc Disord; 1996; 10(4):192-6. PubMed ID: 8939278
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.